Phaseline

Companies › Areteia Therapeutics

Areteia Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Respiratory.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Dexpramipexole Dihydrochloride–Phase 3Eosinophilic Asthma; Chronic Obstructive Pulmonary Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05748600Dexpramipexole DihydrochloridePhase 3Eosinophilic AsthmaRespiratorySep 2025
NCT06533553Dexpramipexole DihydrochloridePhase 2Chronic Obstructive Pulmonary DiseaseRespiratoryOct 2025

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Biotest PureTech Renovion Youssef Yammine Kringle Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.